Compare
Electromed, Inc. vs Ceribell, Inc. vs Vaso Corp vs Biolife Solutions Inc
| Latest fiscal year | Electromed, Inc. ELMD | Ceribell, Inc. CBLL | Vaso Corp VASO | Biolife Solutions Inc BLFS |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $73.78M | $89.06M | $89.10M | $96.21M |
| Revenue growth (YoY) | +15.3% | +36.1% | +2.7% | +28.9% |
| Gross margin | 78.5% | 87.9% | 61.4% | 64.6% |
| Operating margin | 18.8% | -65.6% | -3.2% | -17.3% |
| Net margin | 15.3% | -60.0% | 1.8% | -4.8% |
| Net income | $11.30M | -$53.41M | $1.57M | -$4.59M |
| EPS (Diluted) | $1.30 | -$1.46 | $0.01 | -$0.10 |
| Operating cash flow | $9.66M | -$40.81M | $9.27M | $20.11M |
| Free cash flow | $8.41M | -$41.58M | n/a | $10.64M |
| Cash & equivalents | $20.45M | $40.48M | $35.05M | $33.04M |
| Total assets | $66.27M | $195.80M | $88.35M | $405.88M |
| Total liabilities | $12.29M | $40.47M | n/a | $34.00M |
| Shareholders' equity | $53.98M | $155.34M | $29.43M | $371.89M |
| Return on year-end equity | 20.9% | -34.4% | 5.3% | -1.2% |
| Shares outstanding | 8.37M | 37.49M | 175.95M | 48.20M |
Revenue, most recent five fiscal years
| Fiscal year | Electromed, Inc. | Ceribell, Inc. | Vaso Corp | Biolife Solutions Inc |
|---|---|---|---|---|
| Latest | $73.78M Ended 2026-06-30 | $89.06M Ended 2025-12-31 | $89.10M Ended 2025-12-31 | $96.21M Ended 2025-12-31 |
| 1 year earlier | $64.00M Ended 2025-06-30 | $65.44M Ended 2024-12-31 | $86.77M Ended 2024-12-31 | $74.65M Ended 2024-12-31 |
| 2 years earlier | $54.72M Ended 2024-06-30 | $45.23M Ended 2023-12-31 | $81.02M Ended 2023-12-31 | $68.02M Ended 2023-12-31 |
| 3 years earlier | $48.07M Ended 2023-06-30 | n/a | $79.29M Ended 2022-12-31 | $76.24M Ended 2022-12-31 |
| 4 years earlier | $41.66M Ended 2022-06-30 | n/a | $75.58M Ended 2021-12-31 | $119.16M Ended 2021-12-31 |